Response rate to lenalidomide plus rituximab (R-2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.-MedSci.cn

Response rate to lenalidomide plus rituximab (R-2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.

Andorsky, D; Coleman, M; Yacoub, A; Melear, JM; Brooks, HD; Fanning, SR; Kolibaba, KS; Lansigan, F; Reynolds, C; Li, JH; Liu, DF; Llorente, M; Ricker, JL; Sharman, JP

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (15):

科室
- - 订阅+
  - 更多科室
工具
服务